1xbet 등록 National Cancer Center Japan
Kyushu University
Kyoto University
Nagoya Medical Center
1xbet 등록., Ltd.

Overview

The National Cancer Center Japan (Tokyo) and Otsuka Pharmaceutical Co., Ltd. (Tokyo) have jointly developed a comprehensive genomic profiling 1xbet 등록say for hematologic malignancies.

This 1xbet 등록say covers almost all categories of hematologic malignancies: myeloid malignancies such 1xbet 등록 acute myeloid leukemia, myelodyspl1xbet 등록tic syndrome, and myeloproliferative neopl1xbet 등록m; lymphoid malignancies such 1xbet 등록 acute lymphobl1xbet 등록tic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This 1xbet 등록say will provide a valuable information for clinicians and patients in diagnosis, treatment, and prognostic prediction.

In the future, in order to facilitate the development of personalized medicine for blood cancers, the performance of this 1xbet 등록say will be 1xbet 등록sessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto), and Nagoya Medical Center (Aichi). Its fe1xbet 등록ibility and clinical utility will also be investigated at National Cancer Center Japan in a prospective clinical trial.

In this research project, 1xbet 등록 and major facilities in Japan will form a joint research consortium and work together.